Revolution Medicines, Inc.

Revolution Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on precision oncology. It develops small-molecule therapies designed to target RAS-addicted cancers, with its pipeline centered on RAS(ON) inhibitors and related combination approaches.

7.14

7.14

— Revolution Medicines, Inc.
%
RAS(ON) Inhibitors0% Small-molecule therapies designed to inhibit the active, GTP-bound form of RAS in cancer cells.
Precision Oncology Pipeline0% Clinical and preclinical oncology programs built around genetic drivers and resistance biology.
Combination Therapy Development0% Programs that test RAS-targeted agents with other therapies to improve response and durability.
Collaboration Revenue100% Research collaboration arrangements that support discovery and biomarker work.

The company’s direct counterparties are primarily pharmaceutical collaborators, research partners, and contract...

  • Research collaboratorssecondary

    Pharmaceutical and biotech partners that support discovery, preclinical work, or biomarker programs.

  • Clinical trial sites and investigatorsprimary

    Cancer centers and physicians that enroll patients and generate clinical data for pipeline advancement.

  • Future oncology prescribersprimary

    Oncologists who would prescribe approved RAS-targeted therapies in relevant cancer indications.

  • Third-party payorsprimary

    Commercial insurers and government programs that determine coverage, pricing, and reimbursement.

Revolution Medicines is headquartered in the United States and expects its first commercial launch, if approved, to be...

  • •Headquartered in the United States
  • •First expected commercial launch would be in the U.S.
  • •Europe and Asia are planned follow-on markets
  • •International reimbursement rules can affect pricing and access
  • •Manufacturing is outsourced to third-party CDMOs

The company is building a portfolio of RAS(ON) inhibitors for RAS-addicted cancers and intends to retain meaningful...

01
Advance lead RAS(ON) inhibitor programsshort-term

Clinical proof of concept is central to validating the platform and creating future product value.

02
Build combination and biomarker capabilitiesmedium-term

Combination regimens and biomarker insights can improve response rates and patient selection.

03
Prepare for commercialization in major marketsmedium-term

A direct launch model requires medical, regulatory, manufacturing, and market access readiness.

The business depends on successful clinical development of unproven RAS-targeted therapies, and failure in preclinical...

critical

Clinical development failure

Pipeline value depends on demonstrating safety and efficacy in human trials.

Scope
Lead RAS(ON) inhibitor programs
Materiality
high
high

Scientific uncertainty around direct RAS inhibition

The target has historically been difficult to drug, so the mechanism may not translate into durable approvals.

Scope
RAS(ON) platform
Materiality
high
high

Financing risk

The company will need substantial capital before product sales can fund operations.

Scope
Development and commercialization build-out
Materiality
high
medium

Reimbursement and pricing pressure

Oncology drugs depend on coverage decisions and may face price controls or negotiation.

Scope
U.S., Europe, and Asia commercialization
Materiality
medium
medium

Manufacturing and supply dependence

All manufacturing is outsourced to CDMOs, creating third-party execution and quality risk.

Scope
Clinical and future commercial supply
Materiality
medium
Research and development expense accruals
Can shift quarterly operating loss materially
Collaboration revenue recognition
Affects timing and amount of non-product revenue
Liability related to sale of future royalties
Can create significant non-cash balance-sheet and P&L volatility
Prepaid R&D and deferred advance payments
Affects expense timing across reporting periods

Black Diamond Therapeutics, Inc.

BDTX · Biological Products, (No Diagnostic Substances)

Erasca, Inc.

ERAS · Pharmaceutical Preparations

BridgeBio Oncology Therapeutics, Inc.

BBOT · Pharmaceutical Preparations

Praxis Precision Medicines, Inc.

PRAX · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

RenovoRx, Inc.

RNXT · Pharmaceutical Preparations

: 29/04/2026